PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19763031-5 2009 Plasma malondialdehyde (MDA) level was measured for lipid peroxidation product and erythrocyte SOD and GPx activities as enzymatic antioxidants. Malondialdehyde 7-22 superoxide dismutase 1 Homo sapiens 95-98 31656914-2 2019 The superimposed antioxidant activity of caffeine with SOD was investigated by detecting the concentration of malondialdehyde (MDA) present in cells, which was induced by hyperthermia and heavy metal exposure. Malondialdehyde 110-125 superoxide dismutase 1 Homo sapiens 55-58 31656914-2 2019 The superimposed antioxidant activity of caffeine with SOD was investigated by detecting the concentration of malondialdehyde (MDA) present in cells, which was induced by hyperthermia and heavy metal exposure. Malondialdehyde 127-130 superoxide dismutase 1 Homo sapiens 55-58 31475569-2 2021 Furthermore, the interaction behaviors of malondialdehyde (MDA) with Cu/Zn superoxide dismutase (SOD1) enzyme were elucidated by molecular docking. Malondialdehyde 42-57 superoxide dismutase 1 Homo sapiens 97-101 30958045-6 2019 There were also significant (P < .05) group x time interactions for superoxide dismutase (SOD), glutathione peroxidase (GPx), and malondialdehyde (MDA), with SOD increasing (Delta226 [121] U/gHb) in the OCT group, while GPx decreased (Delta20 [13] U/gHb) and MDA increased (Delta72 [0.04] nmol/mL) in the CON group. Malondialdehyde 133-148 superoxide dismutase 1 Homo sapiens 161-164 28727070-9 2017 In STR, the oxidative stress marker malondialdehyde protein and concentration were increased in HS ( = 0.007) compared to TN and PFTN, which was matched by an inadequate antioxidant response, including an increase in superoxide dismutase (SOD) I ( = 0.03) and II relative protein abundance ( = 0.008) and total SOD activity ( = 0.02) but a reduction ( = 0.006) in catalase activity in HS compared to TN. Malondialdehyde 36-51 superoxide dismutase 1 Homo sapiens 239-242 28727070-9 2017 In STR, the oxidative stress marker malondialdehyde protein and concentration were increased in HS ( = 0.007) compared to TN and PFTN, which was matched by an inadequate antioxidant response, including an increase in superoxide dismutase (SOD) I ( = 0.03) and II relative protein abundance ( = 0.008) and total SOD activity ( = 0.02) but a reduction ( = 0.006) in catalase activity in HS compared to TN. Malondialdehyde 36-51 superoxide dismutase 1 Homo sapiens 311-314 23607226-4 2013 METHODS: Malonyl-dialdehyde (MDA) endproduct of lipid peroxidation and activities of the antioxidant enzymes: superoxide dismutase (SOD), catalase (C-ase), glutathione peroxidase (GP-ase) and reduced glutathione (GSH) were biochemically determined from plasma and red blood cells. Malondialdehyde 29-32 superoxide dismutase 1 Homo sapiens 132-135 22425406-5 2012 RESULTS: SOD1 treatment diminished high glucose-induced oxidative stress, as evidenced by 4-hydroxynonenal and malondialdehyde reductions, and it blocked high glucose-increased iNOS expression, iNOS-luciferase activities, and nitrosylated protein. Malondialdehyde 111-126 superoxide dismutase 1 Homo sapiens 9-13 21383993-5 2011 Superoxide dismutase (SOD) directly inhibits the generation of free radicals and compounds that are produced during oxidation by ROS, such as malonyldialdehyde (MDA). Malondialdehyde 142-159 superoxide dismutase 1 Homo sapiens 0-20 21383993-5 2011 Superoxide dismutase (SOD) directly inhibits the generation of free radicals and compounds that are produced during oxidation by ROS, such as malonyldialdehyde (MDA). Malondialdehyde 142-159 superoxide dismutase 1 Homo sapiens 22-25 21383993-5 2011 Superoxide dismutase (SOD) directly inhibits the generation of free radicals and compounds that are produced during oxidation by ROS, such as malonyldialdehyde (MDA). Malondialdehyde 161-164 superoxide dismutase 1 Homo sapiens 0-20 21383993-5 2011 Superoxide dismutase (SOD) directly inhibits the generation of free radicals and compounds that are produced during oxidation by ROS, such as malonyldialdehyde (MDA). Malondialdehyde 161-164 superoxide dismutase 1 Homo sapiens 22-25 19895330-9 2010 Further analysis of effects of SOD1 SNPs found that those carrying GG genotype of rs10432782 had significantly higher SOD1 activity (p = 0.022), but a significantly lower level of malondialdehyde in plasma, compared with TT carriers (p = 0.007). Malondialdehyde 180-195 superoxide dismutase 1 Homo sapiens 31-35 23105467-0 2004 Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Malondialdehyde 72-87 superoxide dismutase 1 Homo sapiens 0-20 15734282-5 2005 SOD activity and lipid peroxidation, as shown by accumulation malonyldialdehyde (MDA), were detected by biochemical assay. Malondialdehyde 62-79 superoxide dismutase 1 Homo sapiens 0-3 15734282-5 2005 SOD activity and lipid peroxidation, as shown by accumulation malonyldialdehyde (MDA), were detected by biochemical assay. Malondialdehyde 81-84 superoxide dismutase 1 Homo sapiens 0-3 16636496-6 2006 Superoxide dismutase (SOD) and reduced glutathione (GSH) and reduction of oxidative material in the body and the endproduct of lipid peroxidation, malondialdehyde (MDA), were measured as oxidative stress markers. Malondialdehyde 164-167 superoxide dismutase 1 Homo sapiens 0-20 12682418-8 2003 The mean malondialdehyde levels in the patients at baseline were higher than controls (5.91 +/- 1.23 nmol/ml vs 4.55 +/- 1.51 nmol/ml, P = 0 001), so also was plasma alpha-tocopherol levels (P < 0 001), while SOD levels were lower in the patients compared to controls (1692 +/- 259 units g/Hb vs 2451 +/- 131 units g/Hb, P < 0 001). Malondialdehyde 9-24 superoxide dismutase 1 Homo sapiens 212-215 9324399-2 1997 Two-month treatment with SOD and selenium had no effect on the level of ferritin but reduced the concentration of malonic dialdehyde (MDA) in the native erythrocytes in patients with chronic lymphoid leukemia practically to that in healthy individuals. Malondialdehyde 114-132 superoxide dismutase 1 Homo sapiens 25-28 11836988-5 2001 Early intrabronchial instillation of homogenic SOD increases the total antioxidative activity, the level of SOD and catalase, decreases the content of malonic dialdehyde in the sediment of broncho-alveolar lavage and in blood. Malondialdehyde 151-169 superoxide dismutase 1 Homo sapiens 47-50 8891455-1 1996 This study attempted to verify the existence of a relationship between oxidative stress documented by malondialdehyde (MDA) and superoxide dismutase (SOD) and fibrinolysis analysed by tissue plasminogen activator (tPA) and its inhibitor (PAI-1) in diabetes mellitus. Malondialdehyde 102-117 superoxide dismutase 1 Homo sapiens 128-148 8889709-8 1996 Otherwise low SOD levels in analyzed infertile subgroups inversely related to elevated malonaldehydes. Malondialdehyde 87-101 superoxide dismutase 1 Homo sapiens 14-17 8889709-9 1996 Because diminished activity of SOD in seminal plasma was associated with increased levels of malonaldehydes and XO, we could postulate some significance of these monitored substances in evaluation of the cause of male infertility. Malondialdehyde 93-107 superoxide dismutase 1 Homo sapiens 31-34 33360507-8 2021 Enzymatic results confirmed that the SOD nanoformulation reduced malondialdehyde expression and increased glutathione level in the ocular tissues, and thereby down-regulated oxidative stress and prevented RGC loss. Malondialdehyde 65-80 superoxide dismutase 1 Homo sapiens 37-40 7712531-11 1995 The activity of superoxide dismutase (SOD) in diabetic group increased from 598 +/- 105 to 696 +/- 103 U/g of hemoglobin (p < 0.01), the activity of glutathion peroxidase (GSHPx) did not change, malondialdehyde (MDA) decreased from 7.1 +/- 1.1 to 5.8 +/- 1.1 mumol/L (p < 0.01) and uric acid decreased from 261 +/- 83 to 236 +/- 96 mumol/L (p < 0.01). Malondialdehyde 198-213 superoxide dismutase 1 Homo sapiens 16-36 7712531-11 1995 The activity of superoxide dismutase (SOD) in diabetic group increased from 598 +/- 105 to 696 +/- 103 U/g of hemoglobin (p < 0.01), the activity of glutathion peroxidase (GSHPx) did not change, malondialdehyde (MDA) decreased from 7.1 +/- 1.1 to 5.8 +/- 1.1 mumol/L (p < 0.01) and uric acid decreased from 261 +/- 83 to 236 +/- 96 mumol/L (p < 0.01). Malondialdehyde 198-213 superoxide dismutase 1 Homo sapiens 38-41 7712531-11 1995 The activity of superoxide dismutase (SOD) in diabetic group increased from 598 +/- 105 to 696 +/- 103 U/g of hemoglobin (p < 0.01), the activity of glutathion peroxidase (GSHPx) did not change, malondialdehyde (MDA) decreased from 7.1 +/- 1.1 to 5.8 +/- 1.1 mumol/L (p < 0.01) and uric acid decreased from 261 +/- 83 to 236 +/- 96 mumol/L (p < 0.01). Malondialdehyde 215-218 superoxide dismutase 1 Homo sapiens 16-36 7712531-11 1995 The activity of superoxide dismutase (SOD) in diabetic group increased from 598 +/- 105 to 696 +/- 103 U/g of hemoglobin (p < 0.01), the activity of glutathion peroxidase (GSHPx) did not change, malondialdehyde (MDA) decreased from 7.1 +/- 1.1 to 5.8 +/- 1.1 mumol/L (p < 0.01) and uric acid decreased from 261 +/- 83 to 236 +/- 96 mumol/L (p < 0.01). Malondialdehyde 215-218 superoxide dismutase 1 Homo sapiens 38-41 2130596-2 1990 Superoxide dismutase (SOD) in brain tissue was measured by chemoluminescence, malondialdehyde (MDA) by fluorescence spectrometry and leukotrienes (LT) by bioassay. Malondialdehyde 78-93 superoxide dismutase 1 Homo sapiens 0-20 2630018-2 1989 It was found that after iron particles were implanted into the vitreous bodies (1) iron concentration in the aqueous humour rose rapidly and significantly (n = 24, P less than 0.01), (2) malondialdehyde (MDA) a degradation metabolite of lipid peroxidation, in the retinas increased significantly (n = 24, P less than 0.05), and (3) superoxide dismutase (SOD) activity decreased (n = 11, P less than 0.05). Malondialdehyde 187-202 superoxide dismutase 1 Homo sapiens 332-352 2630018-2 1989 It was found that after iron particles were implanted into the vitreous bodies (1) iron concentration in the aqueous humour rose rapidly and significantly (n = 24, P less than 0.01), (2) malondialdehyde (MDA) a degradation metabolite of lipid peroxidation, in the retinas increased significantly (n = 24, P less than 0.05), and (3) superoxide dismutase (SOD) activity decreased (n = 11, P less than 0.05). Malondialdehyde 187-202 superoxide dismutase 1 Homo sapiens 354-357 32700888-6 2022 The activities of SOD and MDA were detected by total superoxide dismutase assay kit and malondialdehyde assay kit. Malondialdehyde 88-103 superoxide dismutase 1 Homo sapiens 18-21 32412100-5 2020 KEY FINDINGS: Radiation reduced superoxide dismutase (SOD) activity and expressions of cyclin-dependent kinase (CDK2), CDK4, cyclin E and transcription factor E2F1 proteins, and increased expressions of p21, p16, cyclin D and retinoblastoma (RB) proteins, malondialdehyde (MDA) activity, SA-beta-gal-positive cells and cells stagnating in G1 phase. Malondialdehyde 256-271 superoxide dismutase 1 Homo sapiens 54-57 32412100-5 2020 KEY FINDINGS: Radiation reduced superoxide dismutase (SOD) activity and expressions of cyclin-dependent kinase (CDK2), CDK4, cyclin E and transcription factor E2F1 proteins, and increased expressions of p21, p16, cyclin D and retinoblastoma (RB) proteins, malondialdehyde (MDA) activity, SA-beta-gal-positive cells and cells stagnating in G1 phase. Malondialdehyde 273-276 superoxide dismutase 1 Homo sapiens 54-57